Synthesis and Characterization of Designed Guaifenesin Prodrugs by أمين محمود عبد المنعم ثوابته & Amin Mahd A. Thawabteh
 
Deanship of Graduate Studies 
 
Al-Quds University 
 
 
 
 
 
 
 
 
Synthesis and Characterization of Designed  
Guaifenesin Prodrugs 
 
 
 
 
Ameen Mahmoud Thewabteh 
 
 
 
 
M .Sc. Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jerusalem – Palestine 
 
1435/2014 
Synthesis and Characterization of Designed  
Guaifenesin Prodrugs 
 
 
 
 
 
 
 
 
Prepared By: 
Ameen Mahmoud Thewabteh 
 
 
 
 
 
 
B.Sc.: Chemistry. Al- Quds University, Palestine. 
 
 
 
Supervisor: Prof. Rafik Karaman 
 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfillment of requirements 
for the degree of Master of Pharmaceutical Industry in 
Applied and Industrial Technology Program, Al-Quds 
University. 
 
 
 
 
 
 
 
 
 
 
 
Jerusalem – Palestine 
 
1435/2014
 Al-Quds University 
 
Deanship of Graduate Studies  
 
Applied and Industrial Technology Program 
 
 
 
 
Thesis Approval 
 
 
 
 
Synthesis and Characterization of Designed  
Guaifenesin Prodrugs  
 
 
Student Name: Ameen Mahmoud Thewabteh 
 
 
 
Registration No.: 20913433 
 
 
 
 
Supervisor: Prof. Rafik Karaman 
 
 
 
 
 
Master thesis Submitted and Accepted, Date: 52/5/5102  
 
 
The names and signatures of the examining committee members are as follows: 
 
1- Head of Committee: Prof. Rafik Karaman Signature:….................... 
2- Internal Examiner: Prof. Imad Odeh  Signature:………………. 
3- 
 
 
External Examiner: Prof. Abdel Naser Zaid Signature:……………… 
 
 
 
 
 
 
Jerusalem – Palestine 
 
1435/2014 
Dedication 
 
 
I dedicate this treatise to my dear country, Palestine. My dear land that I believe 
strongly will return to us some day. 
I dedicate it to all our martyrs who sacrificed and gave their soul to our beloved country 
and to our prisoners who spent their life in the occupation's prisons. 
 
 
To all the above mentioned, I dedicate this work and this success with pride. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
 
 
 
 
 
 
 
Declaration 
 
 
 
I certify that the thesis submitted for the degree of master is the result of my own 
research, except where otherwise acknowledged, and that this thesis (or any part of the 
same) has not be submitted for a higher degree to any bother university or institution. 
 
 
 
 
S i g ne d: . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
Ameen Mahmoud Thewabteh. 
 
D a t e: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II 
 
Abstract: 
 
Guaifenesin is an extremely bitter taste substance which affects its usage in pediatric and 
geriatric formulations. In this thesis we aimed to mask the bitter taste of guaifenesin by 
converting it to a potential tasteless prodrugs using different linkers. The prodrugs were 
synthesized by esterification of carboxylic acid anhydrides and guaifenesin. Maleic 
anhydride, succinic anhydride, and glutaric anhydride, respectively, were used to 
synthesize guaifenesin ester prodrugs (guaifenesin maleate, guaifenesin succinate, 
guaifenesin glutarate), 
1
 H-NMR, LC-MS, and FT-IR have confirmed the identity and 
purity of the new prodrugs.  
 
In vitro kinetic studies for the above mentioned prodrugs were done in four different 
aqueous media: 1 N HCl and buffers pH 3.3, pH 5.5 and pH 7.4. Under the experimental 
conditions the target prodrug was hydrolyzed to release the parent drug, guaifenesin, as 
was confirmed by HPLC determination. The kobs and the corresponding t1/2 values for 
guaifenesin prodrugs in 1N HCl were calculated from the linear regression equation 
correlating the log concentration of the prodrug versus time. The rate constant (kobs) was 
found to be 7.2x10
-4
 for guaifenesin maleate prodrug, 2.54x10
-4
 guaifenesin succinate 
prodrug, and 2.36x10
-4
 guaifenesin glutarate prodrug. Half-lives values (t1/2) were 2.01 
hours for guaifenesin maleate prodrug, 7.03 hours for guaifenesin succinate prodrugs, and 
7.17 hours for guaifenesin glutarate prodrug. On the other hand, at pH 3.3, 5.5 and 7.4, 
guaifenesin maleate, guaifenesin succinate, and guaifenesin glutarate prodrugs were 
entirely stable and no release of the parent drug, guaifenesin, was observed. 
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Chapter One 
 
Introduction 
 
1.1 Background  
 
Many curative drugs have adverse properties that may become pharmacological, 
pharmaceutical or pharmacokinetics barriers in the clinical drug application. Among the 
various approaches to minimize these adverse drug properties while preserving the 
beneficial therapeutic outcome, perhaps the chemical approach that uses drugs 
derivatization offers the highest flexibility and has been demonstrated as a very important 
means for improving drug efficacy. 
The prodrug approach is useful in optimizing the clinical application of the drug, and has 
gained attention as a technique for improving drug therapy in the early 1950’s. 
The term "prodrug" or "pro-agent" was first introduced in 1958 by Albert to describe 
compounds that undergo biotransformation prior to their therapeutic activity.
1 
Prodrugs are 
bioreversible derivatives of drug molecules that undergo an enzymatic or chemical 
transformation in vivo to release the active parent drug, which can then exert the desired 
pharmacological effect.
2 
According to IUPAC (International Union of pure and applied 
chemistry); prodrug is defined as any compound that undergoes biotransformation before 
exerting its pharmacological effect.
3 
Such drug-derivatives have also been called 
"latentiated drugs", "bioreversible derivatives", and "congeners", but "prodrug" is now the 
most commonly accepted term.
4-6 
There are also so called co-drugs or mutual prodrugs 
where a prodrug consists of two pharmacologically active drugs, coupled together to act as 
a promoiety to each other.
7,8
 In drug discovery and development, prodrugs have become an 
established tool for improving physicochemical, biopharmaceutical or pharmacokinetic 
properties of pharmacologically active agents.
9,10 
By applying prodrug technology, the 
clinical usefulness of a drug molecule may be enhanced without modifying the 
3 
 
pharmacological activity of a parent drug. However, the design of an appropriate prodrug 
molecule should ideally be considered at the early stages of preclinical development, 
bearing in mind that prodrugs, while not common, may alter the tissue distribution, 
efficacy and the toxicity of the parent drug. Moreover, promoieties used should ideally be 
safe and rapidly excreted from the body. The schematic representation of the prodrug 
concept is shown in Figure 1.1. 
 
PromoietyDrug molecule
Prodrug
Enzymatic 
and/or chemical
biotrans formation
BARRIER
Drug molecule
PromoietyDrug moleculePromoietyDrug molecule
 
 
Figure (1.1): Schematic representation of the prodrug concept 
 
The choice of promoiety should be considered with respect to the disease state, dose, and 
the duration of therapy. The prodrug approach can be exploited for almost all 
administration routes and dosage forms, and it can be applied to a wide variety of existing 
medicines on the market, as well as to novel drug molecules in the lead optimization step 
early in the drug discovery process.
11-13 
About 5–7% of drugs approved worldwide can be classified as prodrugs, and the 
implementation of a prodrug approach in the early stages of drug discovery is a growing 
trend.
14-16
 The application of modern discovery technologies such as high-throughput 
screening and combinatorial chemistry can produce novel lead compounds with high 
pharmacological potency, but the physicochemical and biopharmaceutical aspects of the 
4 
 
initial leads have frequently been neglected. This can lead to drug candidates with poor 
drug-like properties that face significant problems later in the drug development process.
17 
This is done to increase the usefulness of a drug by improving the physicochemical, 
biopharmaceutical or pharmacokinetic properties of the compound. By chemically modify 
an active agent various barriers can be overcome such as poor aqueous solubility, chemical 
instability, insufficient oral absorption, rapid pre-systemic metabolism, inadequate brain 
penetration, toxicity, local irritation and change the physical form of drug. Prodrugs can 
also prolong the duration of drug action i.e. highly lipophilic prodrugs of steroids and 
neuroleptics that are administrated intramuscular.
 15
 
In most cases a prodrug requires only one or two enzymatic or chemical transformation 
steps to become an active drug.  
 
1.2 Pharmaceutical application of prodrug approach
 
 
The pharmaceutical application can be considered as the phase of expansion involving the 
identification of a new chemical entity with measured or proposed therapeutic potential, 
and its incorporation into a drug delivery system. The delivery system may be one of the 
conventional forms (injections, capsules, tablets, creams or ointments), or a new mode of 
drug delivery such as liposomes or implants.
18
 Two barriers were identified in the 
development phase of commercially usable drug products include: 
(i) Problems of drug formulation: enhancement of permeability and absorption; adverse 
physicochemical properties such as solubility and polarity.  
 (ii) Aesthetic properties: odor, taste (particularly when intended for pediatric usage or oral 
administration).  
 
5 
 
1.2.1 Enhancement of solubility and dissolution rate of drugs 
 
Water solubility is required when dissolution is the rate limiting step in the absorption of 
poorly soluble aqueous agents, or when parental or ophthalmic formulation of such agents 
is desired. Many drugs are hydrophobic in nature and have poor bioavailability.  
The prodrug approach can be applied as a solution for problems such as solubility. 
Hydrophilic drug forms can be produced by reacting half esters such as hemisuccinate, 
hemiglutarates or hemipthalates with the hydroxyl drug functional group. The other half of 
these acidic carriers can form sodium, potassium or amine salts and render the moiety 
more water soluble. For example, chloramphenicol succinate and chloramphenicol 
palmitate, ester prodrugs of chloramphenicol, have enhanced and reduced aqueous 
solubility respectively. On the basis of altered solubility, chloramphenicol sodium 
succinate prodrug is found suitable for parenteral administration.
19 
 
 
1.2.2 Enhancing permeability and absorption  
 
The transport of a drug to its site of action usually requires passage through several lipid 
membranes; therefore, membrane permeability has a considerable influence on drug 
efficacy.
20
 
Prodrug strategies are most commonly employed to increase permeability of compounds 
by masking the polar functional groups and hydrogen bonds with ester or amide linkers 
and therefore increasing lipophilicity. Both permeability by passive diffusion and the 
transporter-mediated process have been addressed with prodrug approaches. Oral delivery 
of ester/amide prodrugs to the curative target is confronted with many physiological, 
chemical, and biochemical barriers. In general, the highest oral bioavailability values that 
ester prodrugs can achieve clinically are 40% to 60%. This is due to incomplete membrane 
permeation, P-glycoprotein efflux, hydrolysis in the GI lumen and intestinal cells, esterase 
6 
 
metabolism in the liver, biliary excretion, and metabolism of the parent. Thus, a successful 
prodrug approach must consider a balance of all these issues.21 
Prodrugs with lipophilic pro-moieties have also been used to promote topical absorption 
for transdermal and ocular drugs. The stratum corneum, the outermost layer of the 
epidermis, represents a high resistance barrier against topical drug delivery. Only the drugs 
with balance of both water and lipid solubility can efficiently penetrate through the layers 
of the skin.
22, 23 
 
 
1.2.3 Masking taste 
 
An unfavorable taste emerges due to sufficient solubility and interaction of a drug with 
taste receptors, a problem which can be solved by lowering the solubility of drug or 
prodrug in the saliva. For example, Chloramphenicol is an extremely bitter substance 
inhibiting its usage in pediatric formulations. Chloramphenicol palmitate, a sparingly 
soluble ester of chloramphenicol, is practically tasteless because of its low aqueous 
solubility. Since the interaction of a drug or prodrug with taste receptors requires the drug 
to be sufficiently soluble in saliva, by lowering the aqueous solubility we can mask the 
unfavorable taste. Later, this prodrug is activated by in vivo hydrolysis to chloramphenicol 
by the action of pancreatic lipase.
24
 
Other examples of the use of prodrugs to mask bitter taste are listed in Table 1.1. 
 
Table (1.1): Prodrug for bitter taste masking
24, 25
 
 
 
Drug Prodrug Reference Year 
 
Clindamycin 
 
 
Alkyl ester 
 
Sinkula et al.  
 
(1973) 
Chloramphenicol 
 
Palmitate or phosphate ester Glazko et al.  (1952) 
Erythromycin 
 
Ethyl succinate or ethyl 
carbonate 
Murphy  (1953) 
Lincomycin Phosphate or alkyl ester Morozowich et al.  (1969, 1973) 
7 
 
1.3 Taste 
 
The tongue and the roof of the mouth are covered with thousands of tiny taste buds. While 
eating, the saliva in the mouth helps break down food. Taste buds contain receptors for 
taste. The perception of taste in humans occurs when molecules interact with these taste 
receptors on the surface of taste buds located in the mouth, mainly on the surface of the 
tongue. This process triggers signals in the mouth which are then sent to the brain where a 
specific taste sensation is recognized and translated as sweet, sour, bitter or salty.  
The receptors for these four tastes are located on different areas of the tongue. Receptors 
responsible for sweet taste are located at the tip of the tongue, receptors for sour taste are 
located along the sides of the tongue, receptors for bitter taste are at the back of the tongue, 
and salty taste receptors are located at the sides and tip of the tongue (Figure 1.2 and 
Table 1.2). These receptors bind molecules by saliva and transmit electrical impulses by 
cranial nerves to the brain where they are translated to the perception of taste.
26
 
Table (1.2): Specific area of tongue.
27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1.2): Locations of taste sensors on the tongue.
26 
 
 
 
 
Taste Area of tongue 
 
Sweet Tip 
 
Salt Tip and sides 
 
Sour Sides 
 
Bitter Back 
 
8 
 
1.4 Taste according to chemical structure 
The solubility of a substance in the saliva determines the strength of taste; the greater the 
solubility of a drug, the greater the concentration of the drug in the saliva at the receptor 
site and thus, an increased sensation of taste.
27
 
Sweet: the sense of this taste is given by many compounds having structural similarity. 
Sugar and glycerin (Figure 1.3A), the two chemical entities are the most common sweet 
substances, consist of polyhydric alcohols containing (CH2OH) groups. Sodium or calcium 
salts of cyclohexyl sulfamic acid (Figure 1.3A) and the dipeptide ester aspartame, used as 
sugar substitutes in the preparation of mouth dissolved tablets, are sweet but require less 
quantity than sugar.
28
 
Sour: the concentration of the hydrogen ion of the tastant is the most important factor that 
determines the strength of sour taste. Therefore, the higher the concentration of hydrogen 
ions in the compound, the stronger is the sense of sour taste. Chemical substances present 
in food such as acetic acid, citric acid and maleic acid (see Figure 1.3B) are responsible 
for stimulating sour taste as these acids are ionized in aqueous solution to produce 
hydrogen ions.
29 
Bitter: compounds that contain phenolic or alcoholic hydroxyl groups, nitro or amino 
groups, esters of aromatic acids, lactones, and sulfur containing aliphatic compounds 
exhibit bitterness. Most pharmaceutical active ingredients such as guaifenesin, 
acetaminophen, ibuprofen, (Figure 1.3C) naproxen, naproxen sodium, psyllium, 
chlorpheniramine, astemizole, loperamide, famotidine, ranitidine, cimetidine, and 
pseudoephedrine are bitter in taste.
30
 
Salty: most of the halide salts such as sodium chloride, sodium bromide, potassium 
chloride and sodium iodide have a salty taste. The sensations of salts shift to bitterness 
9 
 
with an increase in molecular weight. For example, potassium bromide and ammonium 
iodide have a salty, bitter taste while potassium iodide is intensely bitter.
27, 31 
 
HO
OH
OH
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Na+
S
O
O
NH
O-
Sodium cyclamate
O
OH
acetic acid
HO OH
O
OHO
O
OH
citric acid
O
N
H
OH
acetaminophen
O
HO
 ibuprofen
A: Sweet taste
B: Sour taste
C: Bitter taste
 
 
Figure (1.3): Sweet (A), sour (B), and bitter (C) taste compounds structures  
 
 
1.5 Quantitative evaluation of taste 
 
Human sensory evaluation, taking a sample and testing its taste, is the main process to 
measure the taste of a pharmaceutical active ingredient and its formulation. Nevertheless, 
this process is not favored for early stage drug development due to the cost of testing using 
humans, and the fact that the taste of a drug elected might not be important to the final 
product. Therefore, for a long time there has been a demand for taste-sensing detection and 
analytical devices.
32
 
Electronic tongue or e-Tongue is an automated taste sensing device to detect the extent of 
bitterness of drug substance. This device has a transducer composed of various kinds of 
10 
 
lipid/polymer membranes with different characteristics that can be used to detect taste. 
Taste response is transformed into a pattern composed of the electronic signals of the lipid 
membrane potentials. Different response electric potential patterns are obtained for 
substances producing different taste qualities.
33
 
The bitterness quantitative evaluation of medicines is measured by this technique. Basic 
drugs with amine groups in the molecule such as quinine, and anionic drugs as diclofenac 
sodium or salicylic acid, show a comparatively good correlation between the relative 
response electric potential (mV) of channels 1 or 2 for positive drug substance, and 
channel 5 or 6 for negative drug substance of the taste sensor.
34 
 
1.6 Masking bitter taste 
 
There are numerous pharmaceutical preparations containing active ingredients that are 
bitter in taste. With respect to over the counter (OTC) preparations such as cough and cold 
syrups, the bitterness of the preparation is a major problem leading to lack of patient 
compliance, especially in pediatric and geriatric populations, and presents a challenge to 
the pharmacist. In order to ensure patient compliance bitterness masking becomes 
essential.  
 
Taste masking is not an easy or simple procedure. Effort is required before bitter drugs are 
acceptable for market trials. The development of an appropriate formulation involves the 
investment of time, money and resources by pharmaceutical industries to develop palatable 
and pleasant tasting products using various taste masking techniques. 
 
Various methods and technologies are used to mask the unpleasant taste of a drug. Flavor 
enhancers, adding natural flavors, such as anise oil, cardamom, lemon and orange, or 
artificial flavors are the simplest and oldest methods used. Excipient sweetening flavors 
11 
 
such as menthol and chloroform anaesthetize taste receptors, but this method fails to mask 
70% of products.
35
 
Polymer coating and micro-encapsulation are other techniques used to mask the unpleasant 
taste by forming a barrier around the drug particles. By using the right type of coating 
material, the interaction between the drug and taste buds is minimized. The micro-
encapsulation technique is important in taste masking of bitter drugs through encapsulating 
the drug particles by a suitable polymer; the drug has no contact with the taste buds in the 
mouth when dosage forms are given orally to patients.
36,37
 
The unpleasant taste of Diclofenac sodium (DS) was masked by the micro-encapsulation 
technique without any change in the rate of drug release. DS powder was mixed with 
cellulose and lactose and then converted into a spherical core to form a thin, uniform 
microcapsule wall. Diethylphthalate (DEP) and polyethyleneglycol (PEG) were used as 
plasticizers. Ten volunteers tasted the microcapsules. The results demonstrated that the 
extent of taste masking was influenced by the presence of additives (cellulose and lactose) 
within the core; the plasticizer, (DEP and PEG), and core size had an effect on the release 
rate.
38
 
 
The bitter taste can be masked by inclusion complexes such as cyclodextrins (CDs), see 
Figure 1.4. The drug molecule is suitable to accommodate the core of a complexing agent, 
and the cyclodextrins wraps the bad tasting molecule to inhibit its interaction with the taste 
buds.
39CD’s are cyclic oligosaccharides containing six to twelve monosaccharides 
connected by 1 and 4 carbon atoms, were carbon confirmation which in the glucose units 
all secondary hydroxyl groups are located on the wider edge of the ring, and all primary 
hydroxyl groups are located on the narrower edge to form a conical cylinder with a 
hydrophilic outer surface and hydrophobic inner surface. 
12 
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Figure (1.4): Cyclodextrins chemical structures 
The prodrug approach can be used for masking the bitter taste of active pharmaceutical 
ingredients by changing the molecular configuration of the origin molecule and the contact 
of the molecule with taste receptors.  
Most of the above mentioned approaches to mask bitter taste were found to be limited. 
Thus, different strategies should be developed in order to overcome this serious problem. 
In the following study a bitter tastant, guaifenesin (see Figure 1.5), was chosen as a drug 
candidate to be masked by a linker to provide a prodrug without the bitterness of the 
parental drug. 
  
1.7 Guaifenesin 
 
Guaifenesin, the glyceryl ether of guaiacol, is a component of numerous cough and cold 
preparations available worldwide, termed as an expectorant. This medication is most 
commonly used to loosen mucus and phlegm and eventually clear the symptoms of 
congestion resulting from a cold or allergy.
40 
It works by thinning mucus and phlegm in the 
body, and the thinning action makes it easier for the body to expel excess mucus and 
phlegm, generally through coughing or the blowing of the nose.
41
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Guaifenesin is a white to slightly gray, crystalline powder, derived from the resin of 
guaiacum trees, with IUPAC name (RS)-3-(2-methoxyphenoxy)propane-1,2-diol. It is 
soluble in water, freely soluble in alcohol, chloroform and propylene glycol, and sparingly 
soluble in glycerin. It is readily absorbed from the gastrointestinal tract and is rapidly 
metabolized and excreted in the urine (Figure 1.5).
42 
 
O OH
OHO
H3C  
Figure (1.5): Guaifenesin chemical structure. 
 
Guiafenesin was discovered in the 1500’s, but its strong bitter taste made it unacceptable 
for pediatric and geriatric patients, as the bitterness of pharmaceutical medicines plays a 
critical role in patient compliance in prescribing orally administrated drugs.
43
 
The bitter taste of guiafenesin is most likely due to the presence of the hydroxyl groups 
which may interact with the bitter taste receptors forming inter molecular interactions 
(hydrogen bonding). Blocking the hydroxyl groups of guaifenesin has the potential of 
masking its bitterness by decreasing the solubility of guaifenesin in saliva as was reported 
on paracetamol. Paracetamol is a pain killing drug with a strong bitter taste, but its 
derivatives, by which the phenolic group of paracetamol was blocked by an alkyl group, 
lacked the bitterness characteristic of paracetamol.
44
 
Examination of the structures of paracetamol and phenacetin reveals that the only 
difference in the structural features in both is the nature of the group on the para position of 
14 
 
the benzene ring. While in the case of paracetamol the group is hydroxyl, in phenacetin it 
is ethoxy. Another related example is acetanilide that has a chemical structure similar to 
that of paracetamol and phenacetin but it lacks the group in the para position of the 
benzene ring. Figures 1.6 illustrate these points. The combined facts described above 
suggest that the presence of hydroxyl group on the para position is the major contributor 
for the bitter taste of paracetamol. 
 
H
NO
OH
H
NO
O
H
NO
Paracetamol
Phenacetin acetanilide  
Figure (1.6): Paracetamol, phenacetin and acetanilide chemical structures. 
 
"Hence, it is expected that blocking the hydroxyl group in paracetamol with a suitable 
linker could inhibit the interaction of paracetamol with its bitter taste receptor/s and hence 
masking its bitterness." 
44
 
It seems reasonable to assume that the aliphatic hydroxyl group in guaifenesin is crucial 
for obtaining the bitter taste characteristic; this might be due to the ability of guaifenesin to 
interact through hydrogen bonding with bitter taste receptors. 
 
1.8 Guaifenesin dosing information
45-47
 
 
It is available in the form of 200 mg or 400 mg tablets and liquid form (syrup). Each 5ml 
contains 100 mg guaifenesin.  
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Usual Adult Dose of guaifenesin for Cough: 
Immediate release formulation: 200 to 400 mg tablet orally every 4 hours as needed, not to 
exceed 2.4 g/day. Sustained release formulation: 600 to 1200 mg tablet orally every 12 
hours, not to exceed 2.4 g/day. 
Usual Pediatric Dose of guaifenesin for Cough: 
Immediate release formulation: 
 less than 2 years: 12 mg/day syrup orally in 6 divided doses  
 2 to 5 years: 50 to 100 mg syrup orally every 4 hours as needed, not to exceed 600 mg/day 
 6 to 11 years: 100 to 200 mg syrup orally every 4 hours as needed, not to exceed 1.2 g/day 
 12 years or older: 200 to 400 mg tablet orally every 4 hours as needed, not to exceed 2.4 
g/day 
 Sustained release formulation: 
 2 to 5 years: 300 mg syrup orally every 12 hours, not to exceed 600 mg/day 
 6 to 11 years: 600 mg syrup orally every 12 hours, not to exceed 1.2 g/day 
 12 years or older: 600 to 1200 mg tablet orally every 12 hours, not to exceed 2.4 g/day. 
 
1.9 Objectives of the study: 
 
The aims of this research were:  
1. To mask the intensely bitter taste of guaifenesin by synthesizing prodrugs with suitable 
linkers that can release the parent drug (guaifenesin) when exposed to a physiological 
environment.  
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2. To conduct kinetic studies for the intraconversion of the synthesized novel prodrugs to 
their parent drug, guaifenesin using HPLC, and to measure the intraconversion rates and 
the half-lives (t ½) at different buffers 1N HCl, pH 3, pH 5, and pH 7. 
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Chapter Two 
 
Literature review 
 
2.1 Chemical Modification of Clindamycin 
 
Clindamycin is a lincosamide antibiotic. It is usually used to treat infections with anaerobic 
bacteria, but can also be used to treat some protozoa diseases, such as malaria. It is a 
common topical treatment for acne and can be useful against some methicillin-resistant 
infections.
48
 It might be extremely bitter tasting, therefore to make it suitable for intake, the 
dosage is usually given in capsules or coated tablets, but unsuitable for a pediatric 
suspension or chewable tablet dosage form.  
To improve taste properties, a series of 2 and 3 monoesters and some 2,3- dicarbonate ester 
of clindamycin were synthesized. The long chain clindamycin (palmitate and hexadecyl 
carbonate) is virtually devoid of the bitter taste characteristic of clindamycin. 48 
The synthesis of bitterness clindamycin prodrug was achieved by protection of 3,4 
hydroxyl group of clindamycin with acidic anisaldehyde to produce 3,4- anisylidene 
clindamycin. The produced prodrug was then treated by esterfication of hydroxyl group 
number 2 with acid to afford pure clindamycin 2-monoesters ester as a scheme in 
Figure2.1. 
Selective esterification of the 3 hydroxyl groups is achieved by adopting low temperature 
reaction with the use of pyridine as solvent under -25 °C and alkyl chloroformate to 
produce clindamycin 3-monoesters ester as per the scheme in Figure 2.2. 
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Figure (2.1): Clindamycin-2-monoesters 
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Figure (2.2): Clindamycin-3-monoesters 
Taste studies: 
Four derivatives of 2 monoesters, Clindamycin 2-hexylcarbonate HCl, Clindamycin 2-
laurate HCl, Clindamycin 2-palmitate HCl, and Clindamycin 2-diphenylacetate were 
prepared, then dissolved in 30% sucrose solutions and 5-ml of samples of each derivatives 
were given to a taste panel of 26 people. The usual protocol was followed, with 1 hr. span 
between samples. The same protocol was employed for 3 monster derivatives, were the 2 
and 3 monoester derivatives group each tested separately.  
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The average scores shown in Figure 2.3 indicate a linear trend of taste improvement with 
increasing chain length. The palmitate ester is significantly better than the laurate at the 5 
level of confidence. The laurate, in turn, is significantly better than both the hexanoate and 
acetate. The latter two were ranked equally low, being very bitter-tasting compounds. 
Clindamycin 2 and 3 -palmitate hydrochloride are essentially tasteless, for these reasons, it 
is being extensively tested in humans as a tasteless pediatric formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (2.3): Effect of clindamycin ester chain length on taste of ester in syrup. 
 
2.2 Masking the Bitter taste of atenolol. 
 
Based on DFT, MP2, and the density functional from Truhlar group (hybrid GGA: 
MPW1k) calculations for an acid-catalyzed hydrolysis of nine Kirby’s N-alkylmaleamic 
acids and two atenolol prodrugs were designed, Figure 2.4. The calculations demonstrated 
that the amide bond cleavage is due to intramolecular nucleophilic catalysis by the adjacent 
carboxylic acid group and the rate-limiting step is determined based on the nature of the 
amine leaving group. 50 In addition, a linear correlation of the calculated and experimental 
rate values has drawn credible basis for designing atenolol prodrugs that are bitterless, are 
stable in neutral aqueous solutions, and have the potential to release the parent drug in a 
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sustained release manner, Figure 2.5. For example, based on the calculated B3LYP/6-31 G 
(d,p) rates, the predicted  (a time needed for 50% of the prodrug to be converted into drug) 
values for atenolol prodrugs ProD 1-ProD 2 at pH 2 were 65.3 hours (6.3 hours as 
calculated by GGA: MPW1K) and 11.8 minutes, respectively. In vitro kinetic study of 
atenolol prodrug ProD 1 demonstrated that the t1/2 was largely affected by the pH of the 
medium. The determined t1/2 values in 1N HCl, buffer pH 2, and buffer pH 5 were 2.53, 
3.82, and 133 hours, respectively. 51 
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Figure 2.4: Atenolol prodrugs synthesis 
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Figure (2.5): Atenolol prodrugs hydrolysis to parent drug. 
 
2.3 Masking the bitter taste of amoxicillin and cephalexin.
52- 57
 
 
Based on previously reported DFT calculations, amoxicillin ProD 1-2 and cephalexin ProD 
1-2 were designed and synthesized, Figure 2.6. For the intraconversion of both 
antibacterial prodrugs the kobs and t ½ values in different media were calculated from the 
linear regression equation obtained from the correlation of log concentration of the residual 
prodrug verses time. At constant temperature and pH the hydrolysis reaction for the above 
mentioned prodrugs displayed strict first order kinetics as the kobs was quite constant and a 
straight line was obtained. Kinetics studies in 1N HCl, pH 2.5 and pH 5 were selected to 
examine the intraconversion of both prodrugs to their parent drugs, Figure 2.7. The acid-
catalyzed hydrolysis of the prodrugs was found to be much higher in 1N HCl than in pH 
2.5 and pH 5. Amoxicillin released from its prodrug after 3 h in 1 N HCl, 7 h in pH 2.5, 
and 81 h using pH 5, with (kobs’s), 2.47x10
-4
 in HCl, 9.60x10
-5
 in pH 2.5, and 7.55x10
-6
 in 
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pH 5. The released process for cephalexin from its prodrug took 2 h using 1N HCl and 14 
h in pH 2.5, with (kobs’s), 2.57x10
-4
 in HCl and 4.17x10
-5
. The two prodrugs were not 
released to drugs at pH 7.4 and at pH 5 for cephalexin prodrug were quite stable and no 
release of the parent drugs was observed. At pH 5 the hydrolysis of the prodrugs was too 
slow. The two antibacterial prodrugs were found to be bitterless. The bitter taste masking 
by the prodrugs is believed to be via altering the ability of the drug to interact with bitter 
taste receptors.  
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Figure (2.6): Amoxicillin and cephalexin prodrug synthesis 
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Figure (2.7): Amoxicillin and cephalexin prodrug hydrolysis to parent drug 
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Chapter three 
 
Materials and Methods 
 
3.1 General 
 
IR spectra were obtained from a KBr matrix (4000–400 cm-1) using a Perkin-Elmer 
Precisely, Spectrum 100, FT-IR spectrometer. 
The LC-MS system used was Agilent 1200 series liquid chromatography coupled with a 
6520 accurate mass quadruple-time of flight mass spectrometer (Q-TOF LC/MS). The 
analysis was performed in the negative electrospray ionization mode, (Hebrew University). 
The high pressure liquid chromatography (Al-Quds University, HPLC) system consisted of 
an Alliance 2695 module equipped with 2996 Photodiode array detector from Waters 
(Germany). Data acquisition and control were carried out using Empower 2 ™ software 
(Waters, Germany). Analyses were separated with a 4.6 mm x250 mm XBridge® C18 
column (5 μm particle size) used in conjunction with a 4.6x20 mm, XBridge® C18 guard 
column. Micro filters of 0.45μm porosity were normally used (Acrodisc® GHP, Waters). 
1
H-NMR experiments were performed with a Bruker AvanceII 400 spectrometer equipped 
with a 5 mm BBO probe (Hebrew University). pH values were recorded on pH meter 
model HM-30G: TOA electronics ™ was used in this study to measure the pH value of 
each sample, thin-layer chromatography (TLC) was carried out on TLC plastic sheets silica 
gel, 20x20 cm, layer thickness 0.2 mm, the spots on the chromatograms were localized by 
UV light. 
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3.2 Chemicals and Reagents 
Pure standards of guaifenesin were obtained from Merck Ltd., Maleic anhydride, succinic 
anhydride, glutaric anhydride, sodium dihydrogen phosphate anhydrous, sodium 
hydroxide, concentrated hydrochloric acid (36%), sodium hydride (60%) and magnesium 
sulfate anhydrous were commercially obtained from Sigma Aldrich. HPLC grade solvents 
of methanol, acetonitrile, and water were purchased from J.T. Paker. High purity 
chloroform, dimethylformamide (DMF), acetone and diethyl ether (> 99%) were 
purchased from Merck. 
 
 
3.3 Preparation of guaifenesin prodrugs 
Synthesis of the guaifenesin prodrrugs was accomplished using Bruice's procedures 
(Figure 3.1 (a, b, and c)). In a 250 mL round-bottom flask guaifenesin (10 mmol) was 
dissolved in 50 ml of dry dimethylformamide (DMF), 0.8 gm of sodium hydride was 
added, the resulting solution was stirred for 30 minutes then (20 mmol) of maleic 
anhydride, succinic anhydride or glutaric anhydride was slowly added to the mixture, then 
the mixture was stirred overnight. 1N HCl (50 mL) was added while the round-bottom 
flask is setting in an ice bath. The aqueous layer was extracted with ether (3x90 mL) and 
the combined ether layers was dried over MgSO4 anhydrous, filtered and evaporated to 
dryness. The product was washed with hexane and dried. Reactions of guaifenesin with 
maleic anhydride, succinic anhydride or glutaric anhydride provided guaifenesin maleate, 
guaifenesin succinate, and guaifenesin glutarate respectively in yields of 61.5% (1.8 gm) 
for guaifenesin maleate, 58% (1.7 gm) for guaifenesin succinate and 58% (2.12 gm) for 
guaifenesin glutarate. The resulted guaifenesin prodrugs were tested by 
1
H-NMR, FTIR, 
LC-MS and HPLC. 
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 Figure (3.1a): Synthesis scheme for the preparation of guaifenesin maleate prodrug.  
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Figure (3.1b): Synthesis scheme for the preparation of guaifenesin succinate prodrug. 
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Figure (3.1c): Synthesis scheme for the preparation of guaifenesin glutarate prodrug. 
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Guaifenesin [CH3OC6H4OCH2CHOHCH2OH]: 
1
H-NMR (CDCl3, δ ppm): CH3OC6H4: 6.88-7.10 (m, 4H), OCH2CHOH: 4.13 (m, 1H), 
OCH2CHOH: 4.06 (m, 2H), CH3OC6H4: 3.85 (s, 3H), HOCHCH2OH: 3.79 (m, 2H). 
Guaifenesin maleate [CH3OC6H4OCH2CHOHCH2O.CHCHOH 2(CO)]: 
Yield: 1.80 gm (61.5%) 
1
H NMR (CDCl3, δ ppm): CH3OC6H4: 6.88-7.15 (m, 4H), CHCHOH 2(CO): 6.31-6.14 (m, 
2H), OCH2CHOH: 4.27 (m, 1H), HOCHCH2O: 4.03-4.23 (m, 2H), OCH2CHOH: 3.98-
4.10 (m, 2H), CH3OC6H4: 3.86 (s, 3H).  
FT-IR: group frequency (cm
-1
): OCH2CHOH: 3063 cm
-1
, C=O stretch of carboxylic acid: 
1738 cm
-1
, CH=CH: 1634 cm
-1
), M/z 295 gm/mol were analyzed using LC-MS. 
 
Guaifenesin succinate [CH3OC6H4OCH2CHOHCH2OCH2CH2OH 2(CO):  
Yield: 1.70 gm (58%) 
1
H-NMR (CDCl3, δ ppm): CH3OC6H4: 6.88-7.12 (m, 4H), OCH2CHOH: 4.48 (m, 1H), 
HOCHCH2O: 4.09-4.31 (m, 2H), OCH2CHOH: 4.03-4.24 (m, 2H), CH3OC6H4: 3.84 (s, 
3H), CH2CH2OH: 2.97 (m, 4H). 
FT-IR: group, frequency (cm
-1
): OCH2CHOH: 3017 cm
-1
, C=O stretch of carboxylic acid: 
1738 cm
-1
, and M/z 297 gm/mol were analyzed using LC-MS.  
Guaifenesin glutarate [CH3OC6H4OCH2CHOHCH2OCH2CH2CH2OH 2(CO)]: 
Yield: 2.12 gm (58%) 
1
H-NMR (CDCl3, δ ppm): CH3OC6H4: 6.87-7.09 (m, 4H), OCH2CHOH: 4.50 (m,1H), 
HOCHCH2O: 4.16-4.33 (m, 2H), OCH2CHOH: 4.05-4.24 (m, 2H), CH3OC6H4: 3.70 (s, 
3H), CH2CH2CH2OH: 2.39-2.45 (m, 4H), CH2CH2CH2OH: 1.91-1.97 (m, 2H). 
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FT-IR: group, frequency(cm
-1
): OCH2CHOH: 3066 cm
-1
,C=O stretch of carboxylic acid: 
1736 cm
-1
], and M/z 311 gm/mol were analyzed using LC-MS.  
 
3.4 Kinetic Methods 
3.4.1 Buffer preparation 
 
Buffer pH 3.3: 6.8 g potassium dihydrogen phosphate were dissolve in 900 mL water for 
HPLC and the pH was adjusted by diluted phosphoric acid, water was added to reach a 
final volume of 1000 mL. The same procedure was done for the preparation of buffers pH 
5.5 and 7.4, however in these two cases the pH was adjusted using 1 N NaOH. 
 
3.4.2 Calibration curve for guaifenesin and guaifenesin prodrugs 
 
To construct a calibration curve for guaifenesin prodrugs and the parent drug, guaifenesin, 
several concentrations (600, 500, 400, 300, 200 and 100 ppm) were prepared. All samples 
were injected into HPLC-PDA. The optimal HPLC conditions used for the analysis of 
guaifenesin: 4.6 mmx250mm, 5 μm, XBridge ® C18 column, a mixture of water: 
acetonitrile (water pH adjusted to 5.5 using diluted phosphoric acid) (75:25 v/v) as a 
mobile phase, a flow rate of 1 mL/minute and a UV detection at a wavelength of 275 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R
2
 value of 
the plot was recorded. 
 
3.4.3 Preparation of standard and sample solution 
 
500 ppm of standard guaifenesin was prepared by dissolving 50 mg of drug in 100 mL 1N 
HCl, buffer pH 3.3, buffer pH 5.5 or buffer pH 7.4. The sample was injected into HPLC to 
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detect the retention time of guaifenesin. The same procedure was followed for the 
preparation of 500 ppm of each guaifenesin prodrugs.  
 
3.4.4 Hydrolysis of guaifenesin prodrugs 
 
Guaifenesin prodrugs hydrolysis rate were studied at 25
0
C in buffer solutions at different 
pHs (1N HCl, pH 3.3, pH 5.5 and pH 7.4); samples of the reaction mixtures were analyzed 
directly by HPLC, the decreased area percentage of the prodrug peaks and the increased 
area of guaifenesin peaks was monitored each 30 minutes, then area under the peaks of 
guaifenesin and its prodrugs vs. time were plotted. Furthermore the decreased area of the 
prodrugs peaks and the increased area of guaifenesin peaks were monitored in other 
buffers each hour then the area under the peaks of guaifenesin and its prodrugs vs. time 
were plotted. 
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Chapter Four 
 
         Result and discussion 
 
4.1 Results and discussion  
 
We have successfully obtained three guaifenesin prodrugs with three different linkers 
(guaifenesin maleate, guaifenesin succinate, and guaifenesin glutarate). They were 
characterized by FT-IR, 
1
H-NMR and LC-MS techniques, to guarantee pure guaifenesin 
prodrugs that were bitterless taste and were capable of releasing their parental drugs in a 
sustained-release manner as proposed.  
 
4.2 Prodrugs characterization using different analytical techniques  
 
4.2.1. Fourier transforms infrared spectroscopy (FTIR) 
 
The FTIR spectra for the synthesized prodrugs (guaifenesin maleate, guaifenesin succinate, 
and guaifenesin glutarate), Figure 4.2, Figure 4.3, and Figure 4.4, respectively, showed 
prominent peaks that were analyzed and compared to guaifenesin spectra, Figure 4.1. 
The peaks observed in guaifenesin maleate at 3063 cm
-1
, 3017 cm
-1
 in guaifenesin 
succinate, and at 3066 cm
-1
in guaifenesin glutarate are characteristic of the O-H stretching 
seen in carboxylic acids, compared to the peak produced in guaifenesin standard at 3244 
cm
-1
 which in fact comes from the O-H stretch seen in alcohol.  
The prodrugs peak produced at 1455-1454 cm
-1
is characteristic of the CH2 bend of the 
alkyl group. The same peak pattern for the band produced by the guaifenesin standard at 
1455 cm
-1
, and the same for the peaks produced at 1376-1378 cm
-1
 in prodrugs and parent 
drug, guaifenesin, that is characteristic of the CH3 bend. The peaks produced at 1588 cm
-1
 
in guaifenesin maleate, 1595 cm
-1
in guaifenesin succinate, and at 1593 cm
-1
in guaifenesin 
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glutarate, are characteristic of the C=C stretching of the benzene ring in the prodrugs 
compare with the peak produced in the guaifenesin standard at 1594 cm
-1
. 
On the other hand, the peak characteristic of the carbonyl group was seen at 1738 to 
1726cm
-1 
in the three prodrugs only, while the peak at 1634 cm
-1
 is characteristic of the 
C=C stretch (conjugation), found in the guaifenesin maleate IR spectrum only. 
In a conclusion; the gathered information shows that the FT-IR spectrums of the prodrugs 
matches the guaifenesin spectrum in most peaks observed except the peaks of carbonyl 
groups that ranged between 1738-1726 cm
-1
, and C=C stretch (conjugation) at 1634 cm
-1
in 
guaifenesin maleate, in addition to a variation in the range of hydroxyl functional groups 
stretching frequencies between carboxylic acid prodrug functional group and an alcoholic 
OH group of guaifenesin.  
 
Figure (4.1): FT-IR spectrum of guaifenesin standard. 
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Figure (4.2): FT-IR spectrum of guaifenesin maleate. 
 
 
 
Figure (4.3): FT-IR spectrum of guaifenesin succinate. 
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Figure (4.4): FT-IR spectrum of guaifenesin glutarate. 
 
4.2.2: Nuclear magnetic resonance (NMR) 
The H-NMR spectrum of guaifenesin prodrugs, (guaifenesin maleate, guaifenesin 
succinate, and guaifenesin glutarate), Figure 4.6, Figure 4.7, and Figure 4.8, respectively, 
showed characterstic proton chemical shifts when compared with that of guaifenesin 
spectrum, Figure 4.5. 
The methylene proton of (—CH2OH) group appearing at 3.79 ppm in guaifenesin, shifted 
to 4.03-4.23 ppm in guaifenesin maleate prodrug, to 4.09-4.31 ppm in guaifenesin 
succinate, and to 4.16-4.33 ppm in guaifenesin glutarate, this deshielding was mainly due 
to the carbon carbonyl of the acid anhydride linker. 
The singlet at 3.85 ppm is typical of (—OCH3) protons. These protons appeared in the 
same chemical shift range for guaifenesin, and its three prodrugs.  
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The multiplet characteristic of the four aromatic benzene ring protons appeared between 
6.85-7.15 ppm in the guaifenesin prodrugs almost in the same chemical shift range as 
guaifenesin. 
On the other hand, the multiplet signals at 2.67 ppm characteristic of the four methylene 
protons of the (—CH2CH2—) were only seen in guaifenesin succinate. The signals 
produced in guaifenesin glutarate at 1.94 ppm and 2.42 ppm referred to the protons of the 
methylene protons (—CH2CH2CH2—). While the multiplet signals at 6.31–6.41 ppm are 
characteristic of the two ethylene protons (—CH=CH —), found in the guaifenesin maleate 
only. The protons of the methylene group bonded to the alcoholic hydroxyl group (—
CH2OH) were observed at 4.13 ppm in guaifenesin, at 4.27 ppm in guaifenesin maleate, at 
4.48 ppm in guaifenesin succinate, and at 4.50 ppm in guaifenesin glutarate. 
 
Figure (4.5): H-NMR spectrum of guaifenesin. 
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Figure (4.6): H-NMR spectrum of guaifenesin maleate. 
 
Figure (4.7): H-NMR spectrum of guaifenesin succinate 
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Figure (4.8): H-NMR spectrum of guaifenesin glutarate. 
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4.2.3: Liquid chromatography–mass spectrometry (LC-MS) 
To further characterize the synthesized prodrugs (guaifenesin maleate, guaifenesin 
succinate, and guaifenesin glutarate) samples were analyzed by liquid chromatography 
coupled with mass quadruple-time of flight mass spectrometer. The analysis was 
performed in the negative electrospray ionization mode. The corresponding molecular 
masses were obtained (Figure 4.9, 4.10, 4.11). 
Figure (4.9): LC-MS spectrum of guaifenesin maleate. 
Figure (4.10): LC-MS spectrum of guaifenesin succinate. 
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Figure (4.11): LC-MS spectrum of guaifenesin glutarate. 
 
4.3 Hydrolysis studies: 
 
In this part of the study, the stability of the guaifenesin prodrugs (guaifenesin maleate, 
guaifenesin succinate, and guaifenesin glutarate) was investigated using high-performance 
liquid chromatography (HPLC). Appearance of the parent drug (guaifenesin) peak (after 
5.944 min) and disappearance of the prodrug peak (14.999, 10.961, 14.142 min) were 
monitored to determine the rate of conversion for each of the three prodrugs. Kinetic 
studies were performed at constant temperature (37 
o
C) and at the ambient pressure (2421-
2443 psi) in different buffers particularly 1N HCl, pH 3.3 (stomach), pH 5.5 (intestine), 
and pH 7.4 (blood) which corresponds to the physiological environments in the human 
body.  
Calibration curves were made for the three prodrugs. The results show that R² values were 
above 0.95 for all the prodrugs as indicated in Figure 4.12.The hydrolysis monitoring for 
the three prodrugs in 1N HCl, pH 3.3, pH 5.5, and pH 7.4 was conducted and the results of 
the study are summarized in Figures 4.13-4.30. 
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Figure (4.12): Calibration curves of a: guaifenesin, b: guaifenesin maleate, c: guaifenesin 
succinate and d: guaifenesin glutarate. 
 
 
Figure (4.13): Guaifenesin standard. 
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1) Guaifenesin maleate kinetic study at 1N HCl, pH 3.3, pH 5.5 and pH 7.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.14): Guaifenesin maleate prodrug at 1N HCl at zero time (A), after 2.3 (B) and 
5.3 hours (C), [RS: Resolution value]. 
A 
B 
C 
RS: 11.86 
RS: 10.79 
RS: 10.13 
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Figure (4.15): Guaifenesin maleate prodrug at pH 3.3 at t = 0 (A), and after 39 hours (B), 
[RS: Resolution value]. 
 
Figure (4.16): Guaifenesin maleate prodrug at pH 5.5 at t = 0 (A), and after 39 hours (B), 
[RS: Resolution value]. 
 
Figure (4.17): Guaifenesin maleate prodrug at pH 7.4 at t = 0 (A), and after 39 hours (B), 
[RS: Resolution value]. 
 
 
 
A B 
A B 
A B 
RS: 10.11 RS: 11.79 
RS: 10.25 RS: 11.64 
RS: 10.10 RS: 11.82 
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2) Guaifenesin succinate kinetic study at 1N HCl, pH 3.3, pH 5.5 and pH 7.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.18): Chromatograms showing the conversion of Guaifenesin succinate to parent 
drug in 1N HCl at zero time (A), after 6 (B), and 12.8 hours (C), [RS: Resolution value]. 
A 
B 
C 
RS: 6.3 
RS: 3.36 
RS: 3.41 
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Figure (4.19): Guaifenesin succinate prodrug at pH 3.3 at t = 0 (A), after 40 hours (B), 
[RS: Resolution value]. 
 
 
Figure (4.20): Guaifenesin succinate prodrug at pH 5.5 at t = 0 (A), after 40 hours (B), 
[RS: Resolution value]. 
 
Figure (4.21): Guaifenesin succinate prodrug at pH 7.4 at t = 0 (A), after 40 hours (B), 
[RS: Resolution value]. 
 
 
 
A B 
B 
B 
A 
A 
RS: 5.9 RS: 5.7 
RS: 6.0 RS: 5.4 
RS: 5.0 
RS: 5.2 
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3) Guaifenesin glutarate kinetic studies at 1N HCl, pH 3.3, pH 5.5 and pH 7.4. 
 
Figure (4.22): Chromatograms showing the conversion of Guaifenesin glutarate to parent 
drug in 1N HCl at zero time (A), after 6 (B) and 13.75 hours (C), [RS: Resolution value]. 
A 
B 
C 
RS: 7.8 
RS: 4.9 
RS: 6.3 
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Figure (4.23): Guaifenesin glutarate prodrug at pH 3.3 at t = 0 (A), after 40 hours (B), [RS: 
Resolution value]. 
 
Figure (4.24): Guaifenesin glutarate prodrug at pH 5.5 at t = 0 (A), after 40 hours (B), [RS: 
Resolution value]. 
 
Figure (4.25): Guaifenesin glutarate prodrug at pH 7.4 at t = 0 (A), after 40 hours (B), [RS: 
Resolution value]. 
 
 
A 
A 
A 
B 
B 
B 
RS: 7.8 
RS: 7.7 
RS: 9.3 RS: 9.2 
RS: 6.6 RS: 6.3 
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4.4 In vitro intraconversion of guaifenesin prodrugs to their parent drug. 
 
The kinetics of the acid-catalyzed hydrolysis for guaifenesin prodrugs were carried out in 
aqueous buffers in a manner similar to that done by Bruice on Methyl Phenyl Acetals of 
Formaldehyde 
58
 This study investigates whether guaifenesin prodrugs are hydrolyzed to 
release the parent drug, guaifenesin in aqueous medium and to what extent. Acid-catalyzed 
hydrolysis of the synthesized guaifenesin prodrugs were studied in four different aqueous 
media: 1N HCl and buffers pH 3, pH 5 and pH 7.4 and the reaction was monitored by 
HPLC instrument, Figure 4.26. 
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Figure (4.26): Acid-catalyzed hydrolysis of guaifenesin prodrugs. 
The buffered solutions, 1N HCl, pH 3.3 and pH 5.5 were selected to examine the 
interconversion of guaifenesin prodrugs as a stomach simulated pH because as we know 
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pH 1-3 reflects the mean fasting stomach state of the adult, and the pH may increase up to 
5 following ingestion of food. In addition, the second buffer system with pH 5 mimics the 
beginning of the small intestine pathway. The medium, pH 7.4 was selected to examine the 
interconversion of the tested guaifenesin prodrugs in the blood circulation system. 
For guaifenesin prodrugs, at constant temperature and pH, the reaction displayed strict 
first-order kinetics as the kobs was fairly constant and a straight line was obtained by 
plotting log concentration of the guaifenesin prodrugs versus time. The rate constant (kobs) 
for guaifenesin prodrugs in 1N HCl was calculated from the linear regression equation 
correlating the log concentration of the prodrug versus time. The rate constant (kobs) was 
found to be 7.2 x 10
-4
 for maleate prodrug, 2.36 x 10
-4
for succinate prodrug, and 2.54 x 10
-
4
 for glutarate prodrug (see Figure 4.27). Complete hydrolysis of the guaifenesin prodrugs 
to their parent drug, guaifenesinin in 1N HCl requred 6.5 hours for maleate prodrug, 12.8 
hours for succinate prodrug, and 13.75 hours for the glutarate prodrug (see Figure 4.28). 
 
 
 
 
 
Figure (4.27): log concentration of the prodrug versus time to calculate the rate constant 
(kobs). 
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Figure (4.28): Acid-catalyzed hydrolysis of the guaifenesin prodrugs in 1N HCl. 
 
Half-lives (t1/2) for guaifenesin prodrugs in 1N HCl were calculated from the linear 
regression equation correlating the concentration (ppm) of the prodrugs with time. The 
half-lives determined were 2.01 hours for maleate prodrug, 7.03 hours for succinate 
prodrug, and 7.17 hours for the glutarate prodrug (see Figure 4.29). 
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Figure (4.29): concentration of the prodrug versus time to calculate half-lives (t 1/2). 
 
On the other hand, at pH 3.3, 5.5 and 7.4, the prodrugs were entirely stable and no release 
of the parent drug was observed as shown in Figure 4.30 (A, B, C).  
 
 
 
 
 
 
 
 
Figure (4.30A): Kinetic study of guaifenesin prodrugs in pH 3.3,(♦: prodrug, ■: drug). 
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Figure (4.30B): Kinetic study of guaifenesin prodrugs in pH 5.5, (♦: prodrug, ■: drug). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.30C): Kinetic study of guaifenesin prodrugs in pH 7.4, (♦: prodrug, ■: drug). 
54 
 
 
 
 
 
 
 
 
 
 
 
Chapter five 
 
 
 
 
 
 
 
 
Summary and conclusions 
 
 
 
 
 
 
 
 
 
 
55 
 
Chapter Five 
Summary and Conclusions 
Guaifenesin is an extremely bitter taste substance which negatively affects its usage in 
pediatric and geriatric formulations. In this thesis we aimed to mask the better taste of this 
substance by producing a tasteless prodrug using the linker approached. We have 
synthesized three guaifenesin prodrugs (guaifenesin maleate, guaifenesin succinate, 
guaifenesin glutarate) which were fully characteristic by 
1
 H-NMR, LC-MS, and FT-IR.  
 
Kinetic study of the three guaifenesin prodrugs demonstrated that all of them underwent 
intraconversion to the parent drug, guaifenesin. At 1N HCL the half-life values for 
guaifenesin maleate, guaifenesin succinate, and guaifenesin glutarate 2.01 hours, 7.03 
hours and 7.17 hours, respectively. The hydrolysis constant rate for the intraconversion of 
guaifenesin maleate was the highest rate, 7.2X10
-4
, among all others and that for glutarate 
prodrug was the lowest rate, 2.36X10
-4
. This is because in the maleic prodrug there is a 
double bond that creates  more strain which results in a shorter distance between the 
neucleophile and electrophile than in the succinate and glutarate prodrugs. It is worth 
noting that at pH 3.3, 5.5 and 7.4, all three prodrugs were entirely stable and no 
intraconversion of the prodrug to the parent drug was observed. This might be due to the 
fact that the guiafenesen anion (R-O
-
) leaving group is a bad leaving group 
In vitro binding to bitter taste receptor 14 (BTR 14) of prodrugs guaifenesin maleate and 
succinate revealed that both prodrugs did not show any agonist activity. This is in contrast 
to the parent drug, guaifenesin, which has shown a strong agonist activity. 
 
Since the three synthesized novel prodrugs have shown to be cleaved in the stomach 
(acidic medium), where in neutral pH they were entirely stable, formulations of the 
products in natural solutions or syrups are afforded and a high potential to have effective 
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clinical profile. Administration of the prodrugs in syrup form enables the pediatric and 
geriatric to administer the drug without any bitter sensation. Once the prodrug reaches the 
stomach it undergoes hydrolysis to give the parent drug in high yield.   
 
We conclude that the prodrug approach utilized in this study (thesis) is an efficient strategy 
to mask the better taste sensation of guaifenesin and yet provides potential prodrug 
candidates with predictable and acceptable pharmacokinetic profiles.  
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Appendix 
Appendix A: Synthesis Calculations  
 Guaifenesin:  
           
        
               
 
   
 
            
 
           
      
          
            
 
 Sodium hydride (NaH): 
For 1:1 equivalent  
No. of moles NaH = No. of moles guaifenesin  
No. of moles NaH = 0.010 mole 
Then for 1:2 equivalent  
No. of moles NaH = No. of moles guaifenesin X 2.0  
No. of moles NaH = 0.020 mole 
According to equation (A)  
Mass of 100 % NaH = No. of moles x Molecular Mass  
Mass of 100 % NaH = 0.020 mole x 24 g/mole  
Mass of 100 % NaH = 0.480 grams   
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 Maleic Anhydride: 
For 1:1 equivalent  
No. of moles Maleic Anhydride = No. of moles guaifenesin 
No. of moles Maleic Anhydride = 0.010 mole 
Then for 1:2 equivalent  
No. of moles Maleic Anhydride = No. of moles guaifenesin X 2.0 
No. of moles Maleic Anhydride = 0.020 mole  
According to equation (A)  
Mass of Maleic Anhydride = No. of moles X Molecular Mass  
Mass of Maleic Anhydride = 0.020 mole X 98.06 g/mole  
Mass of Maleic Anhydride = 1.96 grams  
 
 Succinic Anhydride: 
For 1:1 equivalent  
No. of moles Succinic Anhydride = No. of moles guaifenesin 
No. of moles Succinic Anhydride = 0.010 mole 
Then for 1:2 equivalent  
No. of moles Succinic Anhydride = No. of moles guaifenesin X 2.0 
No. of moles Succinic Anhydride = 0.020 moles  
According to equation (A)  
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Mass of Succinic Anhydride = No. of moles x Molecular Mass  
Mass of Succinic Anhydride = 0.020 mole x 100.07 g/mole  
Mass of Succinic Anhydride = 2.0 grams  
 
 Glutaric anhydride: 
For 1:1 equivalent  
No. of moles glutaric anhydride = No. of moles guaifenesin 
No. of moles glutaric anhydride = 0.010 mole 
Then for 1:2 equivalent  
No. of moles glutaric anhydride = No. of moles guaifenesin X 2.0 
No. of moles glutaric anhydride = 0.020 mole  
According to equation (A)  
Mass of glutaric anhydride = No. of moles X Molecular Mass  
Mass of glutaric anhydride = 0.020 mole X 114 g/mole  
Mass of glutaric anhydride = 2.28 grams  
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Appendix B: Percent yield (PY) calculation 
 
 Guaifenesin Maleate prodrug:  
 
C10H14O4    +     2 C4H2O3  C14H16O7 
 
Guaifenesin Maleic Anhydride    prodrug   
 
1.98 gm (0.01 mol , 198 gm/mol) of  C10H14O4  was mixed with excess  C4H2O3  (0.02 mol, 
98 gm/mol) and 1.80 gm of  C14H16O7  (0.01 mol, 296.3 gm/mol) was produced . 
TY = 1.98gm C10H14O4  * 
0.01 mol C10H14O4 
198 gm C10H14O4
  * 
0.01 mol C14H16O7 
0.01 mol  C10H14O4  
 * 
296.3 gm C14H16O7
0.01 mol C14H16O7 
  
TY = 2.96 gm of C14H16O7 was expected.  
Percent yield = 61.5% 
Were TY = theoretical yield  
 
 Guaifenesin succinate prodrug:  
 
C10H14O4    +     2 C4H4O3  C14H18O7 
 
guaifenesin succinic Anhydride    prodrug   
 
1.98 gm (0.01 mol , 198 gm/mol) of  C10H14O4  was mixed with excess  C4H4O3  (0.02 mol, 
98 gm/mol) and 1.70 gm of  C14H18O7  (0.01 mol, 298.3 gm/mol) was produced . 
TY = 1.98gm C10H14O4  * 
0.01 mol C10H14O4 
198 gm C10H14O4
  * 
0.01 mol C14H18O7 
0.01 mol  C10H14O4  
 * 
298.3 gm C14H18O7  
0.01 mol C14H18O7 
  
TY = 2.98 gm of  C14H18O7  was expected.  
Percent yield = 58 % 
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 Guaifenesin glutarate prodrug:  
 
C10H14O4    +     2 C5H6O3  C15H20O7 
 
guaifenesin glutaric anhydride    prodrug   
 
1.98 gm (0.01 mol , 198 gm/mol) of  C10H14O4  was mixed with excess  C5H6O3  (0.02 mol, 
98 gm/mol) and 2.12 gm of  C14H18O7  (0.01 mol, 312.3 gm/mol) was produced . 
TY = 1.98gm C10H14O4  * 
0.01 mol C10H14O4 
198 gm C10H14O4
  * 
0.01 mol C15H20O7 
0.01 mol  C10H14O4  
 * 
312.3 gm C15H20O7  
0.01 mol C15H20O7 
  
TY = 3.12 gm of  C15H20O7  was expected.  
Percent yield = 58 % 
 
Appendix C: Calibration curves:  
Table (S1): HPLC data for guaifenesin and prodrugs calibration curves. 
Concentration 
 (ppm) 
Guaifenesin 
AUC 
guaifenesin 
maleate 
AUC 
guaifenesin 
succinate 
AUC 
guaifenesin 
glutarate 
AUC 
 
500 13381831 28703612 1113489 1260140 
400 10859151 23106157 902987 1007264 
300 8502337 17796481 678094 755364 
200 5836530 11773719 450196 513578 
100 3321331 5993449 224752 251788 
Equations Y= 25151X+806131 56615X+402328 2230.3X+4824.1 2510.4X+4509.8 
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Appendix D: Hydrolysis data and calculations 
 Guaifenesin maleate prodrug:  
Table (S2): HPLC data of guaifenesin maleate hydrolysis. 
Time/h drug % prodrug % Area Conc. Ppm Log Conc. 
0 0.2 99.8 29382527 511 2.7 
0.83 15.25 84.75 23726339 321 2.71 
1.5 33 67 18757355 324 2.51 
2 44.33 55.67 12927791 221 2.34 
2.33 50.2 49.67 10953326 186 2.27 
2.66 56.24 43.76 9013694 152 2.18 
3 61.3 38.7 7365445 122 2.08 
3.33 65.63 34.37 6338279 104 2.02 
3.66 70.34 29.66 5424482 88 1.94 
4 72.63 27.37 5250100 85 1.93 
4.33 75.46 24.54 4494666 72 1.85 
4.66 77.42 22.58 4148793 66 1.82 
5 82.33 17.67 3285501 50 1.71 
5.33 84.32 15.68 2998451 45 1.66 
6.33 99.9 0.01 1489 
   
 
The rate constant (kobs) for guaifenesin maleate in 1N HCl was calculated from the linear 
regression equation correlating the log concentration of the prodrug versus time, this 
equation is Y= -0.2133X+2.7725. (Figure 4.27 A).  
Then K obs = 0.2133/296 , were 296gm mol
-1
 is the molar mass of maleate prodrug  
K obs = 7.2x10
-4
 
Half-life (t1/2) for guaifenesin maleate in 1N HCl was calculated from the linear regression 
equation correlating the concentration (ppm) of the prodrugs versus time, this equation is 
Y= -87.958X + 432.4. (Figure 4.29 A). 
 Y= concentration / 2, and X = t ½ . 
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Then t ½ = 255.5 – 432.4 / 87.958, were 255.5 is the initial concentration divided by 2 .  
t ½ of guaifenesin maleate is 2.01 hours.  
 
 Guaifenesin succinate prodrug: 
Table (S3): HPLC data of guaifenesin succinate hydrolysis. 
Time/h drug % prodrug % Area Conc. Ppm Log Conc. 
0 2.33 97.97 1103489 492.6 2.69 
0.75 9.07 90.93 1027339 458.4 2.66 
1.5 11.05 88.95 972882 434 2.63 
2.25 13.89 86.11 948669 423.1 2.62 
3 15.76 84.24 914358 407.8 2.61 
3.75 17.39 82.61 913563 407.4 2.61 
4.5 19.07 80.93 861371 384 2.58 
5.25 23.76 76.24 850404 379.1 2.57 
6 28.44 71.56 808495 360.3 2.55 
6.75 31.57 68.43 773132 344.4 2.53 
7.5 36.86 63.14 713365 317.6 2.5 
8.25 41.55 58.45 660376 293.9 2.46 
9 51.15 48.85 551914 245.2 2.38 
9.75 55.04 44.96 507964 225.5 2.35 
10.5 61.64 38.36 433397 192.1 2.28 
11.3 65.56 34.32 387752 171.6 2.23 
12 70.85 29.14 329228 145.4 2.16 
12.8 80.07 19.93 217376 95.3 1.97 
13.5 92.79 7.25 81912 34.5 1.53 
 
 
The resulted linear equation, Y= -0.0758x + 2.8134, shown in Figure 4.27 B, It represents 
the rate constant (kobs), which equal 2.54x10
-4
. 
The equation Y= -34.428x + 495.85, that indicated in Figure 4.29 B, used to calculated the 
succinate prodrug half-life (t1/2), which equal 7.03 hours. 
 
71 
 
 Guaifenesin glutarate prodrug: 
Table (S4): HPLC data of guaifenesin glutarate hydrolysis. 
Time/h drug % prodrug % Area Conc. Ppm Log Conc. 
0 7.79 92.21 1258940 499.6 2.69 
0.75 19.42 80.58 1100141 436.4 2.63 
1.5 29.26 70.74 1011439 401.1 2.6 
2.25 37.99 62.01 943212 373.9 2.57 
3 53.48 46.52 768063 304.1 2.48 
3.75 57.35 42.65 757792 300 2.47 
4.5 65.46 34.54 691502 273.6 2.43 
5.25 70.73 29.27 614757 243 2.38 
6 73.62 26.38 579581 229 2.35 
6.75 77.4 22.6 535724 211.6 2.32 
7.5 78.81 21.19 521765 206 2.31 
8.25 80.12 19.86 513579 202.7 2.3 
9 81.5 18.5 487640 192.4 2.28 
9.75 83.71 16.29 442497 174.4 2.24 
10.5 85.87 14.13 404041 159.1 2.2 
11.3 89.03 10.97 327971 128.8 2.1 
12 92.4 7.6 241192 94.2 1.97 
12.8 94.72 5.28 174364 67.6 1.82 
 
(kobs) =2.36x10
-4
, was calculated from the eqution Y= -0.0739x + 2.8223. (See Figure 4.27 
C) And (t1/2) was calculated used the equation Y= -34.746x + 499.05 that shown in Figure 
4.29 C. 
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 Resolution values data and calculation: 
 
Table (S5): HPLC data of prodrugs chromatograms. 
Figure Chromatogram RT1   RT2   W1   W2.    Rs 
       
4.14 A Guaifenesin maleate prodrug 
at 1N HCl at 0.0 h 
5.91 14.93 0.21 1.31 11.86 
4.14 B Guaifenesin maleate prodrug 
at 1N HCl after 2.3 h  
5.93 14.99 0.65 1.03 10.79 
4.14 C Guaifenesin maleate prodrug 
at 1N HCl after 5.3 h  
5.87 14.64 0.83 0.90 10.13 
4.15 A Guaifenesin maleate prodrug 
at pH 3.3 at 0.0 h 
5.46 13.85 0.11 1.55 10.10 
4.15 B Guaifenesin maleate prodrug 
at pH 3.3 after 39 h 
5.69 14.63 0.13 1.38 11.82 
4.16 A Guaifenesin maleate prodrug 
at pH 5.5 at 0.0 h 
5.46 13.86 0.09 1.57 10.11 
4.16 B Guaifenesin maleate prodrug 
at pH 5.5 after 39 h 
5.68 14.62 0.08 1.43 11.79 
4.17 A Guaifenesin maleate prodrug 
at pH 7.4 at 0.0 h 
5.45 13.93 0.12 1.53 10.25 
4.17 B Guaifenesin maleate prodrug 
at pH 7.4 after 39 h 
5.69 14.59 0.13 1.39 11.64 
4.18 A Guaifenesin succinate prodrug 
at 1N HCl at 0.0 h 
5.65 10.96 0.38 1.30 6.30 
4.18 B Guaifenesin succinate prodrug 
at 1N HCl after 6.0 h  
5.77 10.87 1.13 1.90 3.36 
4.18 C Guaifenesin succinate prodrug 
at 1N HCl after 12.8 h  
5.81 10.95 1.25 1.76 3.41 
4.19 A Guaifenesin succinate prodrug 
at pH 3.3 at 0.0 h 
5.71 10.76 0.53 1.18 5.90 
4.19 B Guaifenesin succinate prodrug 
at pH 3.3 after 40 h 
5.71 10.79 0.56 1.20 5.70 
4.20 A Guaifenesin succinate prodrug 
at pH 5.5 at 0.0 h 
 
5.75 10.82 0.48 1.21 6.00 
4.20 B Guaifenesin succinate prodrug 
at pH 5.5 after 40 h 
5.71 10.76 0.53 1.31 5.40 
4.21 A Guaifenesin succinate prodrug 
at pH 7.4 at 0.0 h 
5.77 10.91 0.69 1.35 5.00 
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4.21 B Guaifenesin succinate prodrug 
at pH 7.4 after 40 h 
5.72 10.78 0.63 1.31 5.20 
4.22 A Guaifenesin glutarate prodrug 
at 1N HCl at 0.0 h 
5.78 14.14 0.56 1.58 7.80 
4.22 B Guaifenesin glutarate prodrug 
at 1N HCl after 6.0 h  
5.78 13.74 1.2 2.03 4.90 
4.22 C Guaifenesin glutarate prodrug 
at 1N HCl after 13.75 h  
6.00 14.07 1.38 1.16 6.30 
4.23 A Guaifenesin glutarate prodrug 
at pH 3.3 at 0.0 h 
5.98 13.82 0.16 1.83 7.80 
4.23 B Guaifenesin glutarate prodrug 
at pH 3.3 after 40 h 
5.99 13.77 0.12 1.81 7.70 
4.24 A Guaifenesin glutarate prodrug 
at pH 5.5 at 0.0 h 
5.98 14.14 0.18 1.56 9.30 
4.24 B Guaifenesin glutarate prodrug 
at pH 5.5 after 40 h 
5.99 14.14 0.23 1.53 9.20 
4.25 A Guaifenesin glutarate prodrug 
at pH 7.4 at 0.0 h 
6.10 14.70 0.26 2.35 6.60 
4.25 B Guaifenesin glutarate prodrug 
at pH 7.4 after 40 h 
6.20 14.70 0.30 2.40 6.30 
 
The resolution between two peaks in all chromatograph is given by:  
Rs = 2 (RT2 – RT1) / (W1 + W2)  
where RTs are the retention times (min) and Ws are the widths at the baseline of the peaks 
(min). 
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 اــاث العليــعمادة الدراس
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